抗苗勒管激素在绝经过渡期的变化轨迹
基于SWAN多中心多种族围绝经队列,分析1131名有≥3次AMH测量且观察到最终月经的妇女,识别出两种AMH下降轨迹:低起始/慢下降组(39.6%,中位下降1.2 pg/mL/月)和高起始/快下降组(60.4%,6.7 pg/mL/月)。低起始/慢下降与基线年龄较大、BMI较高、非白人种族相关,且独立于绝经前心血管危险因素,与绝经后心血管风险更高及血管舒缩症状报告较少相关。
要点
- AMH下降至最终月经存在两种轨迹:低起始慢下降和高起始快下降。
- 低起始慢下降组占39.6%,中位下降1.2 pg/mL/月;高起始快下降组占60.4%,下降6.7 pg/mL/月。
- 低起始慢下降与绝经后心血管风险更高相关,且独立于绝经前危险因素。
核心结论
- 在SWAN子样本中观察到两种AMH下降轨迹至最终月经,低起始慢下降轨迹与绝经后心血管风险更高独立相关。
研究设计与样本
- SWAN多中心多种族围绝经队列分析,纳入1131名有至少3次围绝经期AMH测量且观察到最终月经的妇女。
主要发现
- 低起始/慢下降组448人(39.6%),中位AMH下降1.2 pg/mL/月;高起始/快下降组683人(60.4%),下降6.7 pg/mL/月。
- 低起始/慢下降组与基线年龄较大、BMI较高、非白人种族和族裔相关。
- 轨迹类别与寡月经史、疑似多囊卵巢综合征史或吸烟状态无关。
- 低起始/慢下降组绝经后心血管风险 profile 更差,且最终月经后报告频繁血管舒缩症状的可能性更低。
临床怎么用
- 对围绝经期AMH下降缓慢且起始水平较低的妇女,应关注绝经后心血管风险。
- AMH轨迹可能有助于识别绝经后心血管风险较高的妇女,但需进一步验证。
局限性
- 研究为观察性队列分析,仅基于SWAN子样本,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze the trajectory of anti-müllerian hormone (AMH) decline leading to the final menstrual period, identify distinct AMH patterns, and assess their association with unique participant characteristics. METHODS: SWAN (Study of Women's Health Across the Nation), a multisite, multiethnic perimenopausal cohort, was analyzed. Included participants had an observed final menstrual period and three or more measurements of AMH levels taken during perimenopause. Statistical modeling was used to identify AMH trajectory classes; participants were placed into predicted class based on best fit. Differences in baseline demographic and health characteristics were assessed by analysis of variance or χ2. Generalized estimating equation models were used to estimate the association between AMH trajectory class and outcomes, accounting for repeated measures. RESULTS: A total of 1,131 women had at least three AMH measurements and an observed final menstrual period. Two AMH trajectory classes were observed: 448 participants (39.6%) with lower initial AMH and slower decline (low/slow [LS] group) and 683 participants (60.4%) with higher AMH and steeper decline (high/fast [HF] group). Participants in the LS group had a median AMH decline of 1.2 pg/mL/month; those in the HF group had a decline of 6.7 pg/mL/month. The LS classification was associated with baseline older age, higher body mass index (BMI), and non-White race and ethnicity. Trajectory classes did not differ by history of oligomenorrhea, presumptive polycystic ovarian syndrome, or smoking status. Participants in the LS group had worse postmenopausal cardiovascular risk profiles and were less likely to report frequent vasomotor symptoms after the final menstrual period. CONCLUSION: Two different AMH trajectories to the final menstrual period were observed in a subsample of SWAN participants. Independent of a participant's premenopausal cardiovascular risk factors, lower starting AMH and slower decline were associated with higher postmenopausal cardiovascular risk.
引用
- Acharya KS, Bozzuto L, Kaizer LK, et al. Anti-Müllerian Hormone Trajectories Across the Menopause Transition. Obstet Gynecol. 2026. PMID: 42945500. doi:10.1097/AOG.0000000000006451
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。